AstraZeneca to invest £11.5 million in clinical oncology bioinformatics deal with University of Manchester

Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Tuesday said it has signed a five-year £11.5 million ($17.4 million), clinical trial bioinformatics agreement with the University of Manchester in a bid to deliver personalised healthcare to cancer patients.

The two organizations will apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time, they said in a joint statement.

The collaboration includes the development of a new bioinformatics system to capture and integrate clinical trial safety, efficacy, biomarker and drug distribution data in real time.